Spontaneous and post-interventional regression of cervical HPV infection

Czech version

Authors: Viktor Procházka ¹; Valeria Skopelidou ¹; Martina Romanová ^1,2; Jaroslav Klát ^1,2
Authors‘ workplace: Ostravská univerzita, Ostrava ¹; Gynekologicko-porodnická klinika FN Ostrava ²
Published in: Ceska Gynekol 2024; 89(5): 400-404
Category:
doi: https://doi.org/10.48095/cccg2024400

Overview

Recent literature sources suggest that 15–20% of all malignant diseases have a viral aetiology. About 5% of these are caused by the human papillomavirus. The presence of papillomavirus is one of the strongest risk factors for development of a cervical pre-cancerous lesion and subsequent cervical cancer. The presented review provides a brief summary and characterisation of risk factors that influence spontaneous and post-interventional regression and persistence of papillomavirus in the cervical area.

Keywords:

cervical cancer – cervical dysplasia – papillomavirus – conisation

Sources

1. Bhattacharjee R, Kumar L, Dhasmana A et al. Governing HPV-related carcinoma using vaccines: bottlenecks and breakthroughs. Front Oncol 2022; 12: 977933. doi: 10.3389/ fonc. 2022.977933.

2. Vonsky M, Shabaeva M, Runov A et al. Carcinogenesis associated with human papillomavirus infection. Mechanisms and potential for immunotherapy. Biochemistry (Mosc) 2019; 84 (7): 782–799. doi: 10.1134/S0006297919070095.

3. Kombe Kombe AJ, Li B, Zahid A, Mengist HM et al. Epidemiology and burden of human papillomavirus and related dis eases, molecular pathogenesis, and vaccine evaluation. Front Public Health 2020; 8: 552028. doi: 10.3389/fpubh.2020.552028.

4. Oyouni AA. Human papillomavirus in cancer: infection, dis ease transmission, and progress in vaccines. J Infect Public Health 2023; 16 (4): 626–631. doi: 10.1016/j.jiph.2023.02.014.

5. Soheili M, Keyvani H, Soheili M et al. Human papilloma virus: a review study of epidemiology, carcinogenesis, dia gnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran 2021; 35: 65. doi: 10.47176/mjiri. 35.65.

6. Petca A, Borislavschi A, Zvanca ME et al. Non-sexual HPV transmission and role of vaccination for a better future. Exp Ther Med 2020; 20 (6): 186. doi: 10.3892/etm.2020.9316.

7. Pruski D, Millert-Kalińska S, Łagiedo M et al. Effect of HPV vaccination on virus eisappearance in cervical samples of a cohort of HPV-positive polish patients. J Clin Med 2023; 12 (24): 7592. doi: 10.3390/jcm12247592.

8. Cortés-Alaguero C, González-Mirasol E, Morales-Roselló J et al. Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia? J Turk Ger Gynecol Assoc 2017; 18 (1): 1–8. doi: 10.4274/jtgga.2016.0138.

9. Kim JW, Song SH, Jin CH et al. Factors affecting the clearance of high-risk human papillomavirus infection and the progression of cervical intraepithelial neoplasia. J Int Med Res 2012; 40 (2): 486–496. doi: 10.1177/147323001204000210.

10. Petry KU, Horn J, Luyten A et al. Punch bio psies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix. BMC Cancer 2018; 18 (1): 318. doi: 10.1186/s12885-018-4225-9.

11. Trimble CL, Piantadosi S, Gravitt P et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005; 11 (13): 4717–4723. doi: 10.1158/1078-0432.CCR-04-2599.

12. Nourrisson A, Lepetit H, Marty M et al. Regression of cervical high-grade squamous intraepithelial lesions (HSIL/CIN2) managed expectantly. J Gynecol Obstet Hum Reprod 2022; 51 (8): 102442. doi: 10.1016/j.jogoh.2022.102442.

13. Song SH, Lee JK, Oh MJ et al. Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix. Int J Gynecol Cancer 2006; 6 (4): 1608–1613. doi: 10.1111/ j.1525-1438.2006.00634.x.

14. Giuliano AR, Sedjo RL, Roe DJ et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13 (9): 839–846. doi: 10.1023/a: 1020668232219.

15. Shew ML, Fortenberry JD, Tu W et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006; 160 (2): 151–156. doi: 10.1001/ archpedi.160.2.151.

16. Mitra A, MacIntyre DA, Ntritsos G et al. The vaginal microbio ta associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat Commun 2020; 11 (1): 1999. doi: 10.1038/s41467-020-15856-y.

17. Wadström H, Frisell T, Sparén P et al. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis 2016; 75 (7): 1272–1278. doi: 10.1136/annrheumdis-2015-208263.

18. Bowden SJ, Doulgeraki T, Bouras E et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and fol low-up Mendelian randomisation studies. BMC Medicine 2023; 21 (1): 274. doi: 10.1186/s12916-023-02965-w.

19. Liu G, Sharma M, Tan N et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018; 32 (6): 795–808. doi: 10.1097/QAD.0000000000001765.

20. Gosvig CF, Huusom LD, Andersen KK et al. Persistence and reappearance of high-risk human papillomavirus after conization. Gynecol Oncol 2013; 131 (3): 661–666. doi: 10.1016/ j. ygyno.2013.09.002.

21. Papalia N, Rohla A, Tang S et al. Defining the short-term dis ease recurrence after loop electrosurgical excision procedure (LEEP). BMC Womens Health 2020; 20 (1): 34. doi: 10.1186/s12905-020-00901-1.

22. Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ 2014; 348: f7361. doi: 10.1136/bmj. f7361.

23. Zhang H, Zhang T, You Z et al. Positive surgical margin, HPV persistence, and expression of both TPX2 and PD-L1 are associated with persistence/recurrence of cervical intraepithelial neoplasia after cervical conization. PLoS One 2015; 10 (12): e0142868. doi: 10.1371/journal.pone.0142868.

24. Zeng Y, Jiang T, Zheng Y et al. Risk factors predicting residual lesion in subsequent hysterectomy fol lowing cold knife conization (CKC) for high-grade squamous intraepithelial lesion (HSIL). BMC Womens Health 2022; 22 (1): 358. doi: 10.1186/s12905-022-01939-z.

25. Spinillo A, Dominoni M, Boschi AC et al. The relationship of human papillomavirus infection with endocervical glandular involvement on cone specimens in women with cervical intraepithelial neoplasia. Gynecol Oncol 2020; 159 (3): 630–635. doi: 10.1016/j.ygyno.2020. 09.034.

26. Jia M, Lan C, Niu J e al. Risk factors for pathological upgrading in perimenopausal women with cervical intraepithelial neoplasia grade 2/3 fol lowing conization. Medicine (Baltimore) 2022; 101 (43): e31368. doi: 10.1097/MD.000 0000000031368.

27. Ding T, Li L, Duan R et al. Risk factors analysis of recurrent dis ease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2023; 160 (2): 538–547. doi: 10.1002/ijgo.14340.

28. Zhang Y, Ni Z, Wei T et al. Persistent HPV infection after conization of cervical intraepithelial neoplasia – a systematic review and meta-analysis. BMC Womens Health 2023; 23 (1): 216. doi: 10.1186/s12905-023-02360-w.

29. Wu Q, Jiang Y, Ding J et al. Clinical predictors of residual dis ease in hysterectomy fol lowing a loop electrosurgical excision procedure for cervical intraepithelial neoplasia grade 3. BMC Pregnancy Childbirth 2022; 22 (1): 971. doi: 10.1186/s12884-022-05281-y.

30. Jing L, Dan W, Zhunan L et al. Residual lesions in uterine specimens after loop electrosurgical excision procedure in patients with CIN. Arch Gynecol Obstet 2018; 298 (4): 805–812. doi: 10.1007/s00404-018-4881-7.

31. So KA, Lee IH, Kim TJ et al. Risk factors of persistent HPV infection after treatment for high--grade squamous intraepithelial lesion. Arch Gynecol Obstet 2019; 299 (1): 223–227. doi: 10.1007/s00404-018-4936-9.

32. Di Donato V, Caruso G, Petrillo M et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines (Basel) 2021; 9 (5): 410. doi: 10.3390/vaccines9050410.

ORCID autorů

V. Procházka 0000-0002-5644-7616

V. Skopelidou 0000-0001-7466-7535

M. Romanová 0000-0002-9555-8546

J. Klát 0000-0001-9762-1345

Doručeno/Submitted: 9. 6. 2024

Přijato/Accepted: 17. 6. 2024

MUDr. Bc. Martina Romanová

Gynekologicko-porodnická klinika

FN Ostrava

17. listopadu 1790/5

708 52 Ostrava-Poruba